Search

Louis W Licamele

from Potomac, MD
Age ~42
Get Report
Related to:
Anton LicameleMary Ann Licamele Melkonian, 45William Licamele, 77Stephanie Chisholm, 62Marc Melkonian, 49Mary A Licamele, 45
Connected to:
Paul R Licameli, 56Daniel J Lican, 38Amalia A Licano, 62Angela Licano, 43Frank I Licano, 73James C Licano, 54Javier Licano, 76Mario A Licano, 64Laura M Licar, 56Hilary A Licardi, 59

Louis Licamele Phones & Addresses

  • 316 Prettyman Dr, Rockville, MD 20850 (301) 251-3730
  • Potomac, MD
  • 301 Cross Green St, Gaithersburg, MD 20878 (301) 977-2522
  • 301B Cross Green St, Gaithersburg, MD 20878 (301) 977-2522
  • Mc Lean, VA
  • Washington, DC
  • College Park, MD

Business Records

Name / Title
Company / Classification
Phones & Addresses
Louis Licamele
Top Executive
Vanda Pharmaceuticals Inc
A Development Stage Company Engaged In The Mfg of Pharmaceutical Preparations & Commercial Physical Research · Mfg Pharmaceutical Preparations & Medical Research · Mfg Pharmaceutical Preparations and Medical Research
2200 Pennsylvania Ave NW, Washington, DC 20037
9605 Med Ctr Dr, Rockville, MD 20850
(240) 599-4500
Louis Licamele
Top Executive, Bioinformatics Scientist
Vanda Pharmaceuticals
Pharmaceuticals · Mfg Pharmaceutical Preparations · Medical Development · A Development Stage Company Engaged In The Mfg of Pharmaceutical Preparations & Commercial Physical Research · Mfg Pharmaceutical Preparations & Medical Research · Mfg Pharmaceutical Preparations and Medical Research · Pharmaceutical Products-Wholes
2200 Pennsylvania Ave NW SUITE 300E, Washington, DC 20037
Washington, DC 20037
9620 Medical Ctr Dr, Rockville, MD 20850
9605 Med Ctr Dr, Rockville, MD 20850
(301) 294-9300, (240) 599-4500, (301) 294-1900

Publications

Us Patents

Prediction Of Qt Prolongation Based On Snp Genotype

View page
US Patent:
20100249188, Sep 30, 2010
Filed:
Sep 10, 2008
Appl. No.:
12/675607
Inventors:
Christian Lavedan - Potomac MD, US
Simona Volpi - Derwood MD, US
Louis Licamele - Gaithersburg MD, US
Kendra Tomino Mack - Westminster MD, US
Callie Michelle Heaton - Washington DC, US
International Classification:
A61K 31/454
C12Q 1/68
A61K 31/5517
A61K 31/519
A61K 31/554
A61K 31/407
A61K 31/496
A61K 31/38
A61K 31/40
A61K 31/452
A61P 25/18
US Classification:
514321, 435 6, 514220, 51425941, 51421113, 514412, 51425402, 514410, 514323, 514431, 514428, 514317
Abstract:
The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.

Genetic Markers For Efficacy Of Iloperidone In The Treatment Of Psychotic Symptoms

View page
US Patent:
20110021566, Jan 27, 2011
Filed:
May 17, 2008
Appl. No.:
12/600036
Inventors:
Christian Lavedan - Potomac MD, US
Simona Volpi - Derwood MD, US
Louis Licamele - Gaithersburg MD, US
Mihael H. Polymeropoulos - Potomac MD, US
International Classification:
A61K 31/445
G06F 19/00
US Classification:
514321, 702 19
Abstract:
Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.

Identification Of A Molecular Signature For Antipsychotics And Serms

View page
US Patent:
20110118313, May 19, 2011
Filed:
May 15, 2009
Appl. No.:
12/991766
Inventors:
Christian Lavedan - Potomac MD, US
Louis Licamele - Gaithersburg MD, US
Mihael H. Polymeropoulos - Potomac MD, US
International Classification:
A61K 31/4535
C12Q 1/68
C40B 30/00
A61K 31/138
A61P 25/00
A61P 25/18
US Classification:
514324, 435 6, 506 7, 514648, 514651
Abstract:
Molecular signature for antipsychotics and SERMs has been identified, namely their upregulation of genes that alter lipid homeostasis, preferably of one or more of the following genes: TNSIG1, SCD, FADS2, LDLR, FDPS, ACAT2, FDFT1, CYP51A1, FASN, DHCR7, RAB26, TM7SF2, SATB1, FAM117, GPNMB, NUPR1, VAC14, and LSS.

Method Of Predicting A Predisposition To Qt Prolongation

View page
US Patent:
20120035215, Feb 9, 2012
Filed:
Apr 5, 2010
Appl. No.:
13/263076
Inventors:
Christian Lavedan - Potomac MD, US
Simona Volpi - Derwood MD, US
Louis Licamele - Gaithersburg MD, US
Assignee:
VANDA PHARMACEUTICALS, INC. - Rockville MD
International Classification:
A61K 31/454
A61P 9/00
C12Q 1/68
US Classification:
514321, 435 611
Abstract:
The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.

Method Of Predicting A Predisposition To Qt Prolongation

View page
US Patent:
20120058201, Mar 8, 2012
Filed:
Apr 5, 2010
Appl. No.:
13/263075
Inventors:
Christian Lavedan - Potomac MD, US
Simona Volpi - Derwood MD, US
Louis Licamele - Gaithersburg MD, US
Assignee:
VANDA PHARMACEUTICALS, INC. - Rockville MD
International Classification:
A61K 33/36
A61K 31/45
A61K 31/517
A61K 31/4706
A61K 31/7048
C12Q 1/68
A61P 9/00
A61K 31/343
A61K 31/40
A61K 31/5415
A61K 31/4402
A61K 31/454
A61K 31/5383
US Classification:
424623, 514321, 514327, 51426624, 514313, 514 29, 5142302, 514469, 514408, 5142262, 514357, 514322, 435 611
Abstract:
The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.

Method Of Predicting A Predisposition To Qt Prolongation

View page
US Patent:
20120059035, Mar 8, 2012
Filed:
Apr 5, 2010
Appl. No.:
13/263077
Inventors:
Christian Lavedan - Potomac MD, US
Simona Volpi - Derwood MD, US
Louis Licamele - Gaithersburg MD, US
Assignee:
VANDA PHARMACEUTICALS, INC. - Rockville MD
International Classification:
A61K 31/454
C12Q 1/68
US Classification:
514321, 435 611
Abstract:
The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.

Treatment Of Circadian Rhythm Disorders

View page
US Patent:
20130197076, Aug 1, 2013
Filed:
Jan 25, 2013
Appl. No.:
13/751011
Inventors:
Vanda Pharmaceuticals, Inc. - Washington DC, US
John Joseph Feeney - Olney MD, US
Louis William Licamele - Potomac MD, US
Mihael H. Polymeropoulos - Potomac MD, US
Assignee:
Vanda Pharmaceuticals, Inc. - Washington DC
International Classification:
A61K 31/343
US Classification:
514469
Abstract:
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Method Of Predicting A Predisposition To Qt Prolongation

View page
US Patent:
20100226858, Sep 9, 2010
Filed:
Mar 28, 2008
Appl. No.:
12/593419
Inventors:
Christian Lavedan - Potomac MD, US
Simona Volpi - Derwood MD, US
Louis Licamele - Gaithersburg MD, US
Kendra Tomino Mack - Westminster MD, US
Callie Michelle Heaton - Washington DC, US
International Classification:
A61K 49/00
A61K 31/454
C12Q 1/68
C12Q 1/02
A61P 9/00
US Classification:
424 92, 514321, 435 6, 435 29
Abstract:
The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Control profile
Louis W Licamele from Potomac, MD, age ~42 Get Report